.Merck & Co.'s TIGIT system has actually endured another obstacle. Months after shuttering a peri...
.After a year specified by pipe cuts, the shift of its own CEO and discharges, Exscientia will merge...
.Cullinan Therapy was impressed sufficient along with Port BioMed's bispecific invulnerable reactor ...
.In this particular week's episode of "The Best Line," we are actually diving right into Tough Biote...
.The confetti is still soaring coming from Eli Lilly's event commemorating the approval of Alzheimer...
.Welcome to this week's Chutes & Ladders, our roundup of considerable leadership hirings, firings...
.Complying with an unsatisfactory presenting for Lykos Therapies' MDMA prospect for post-traumatic s...
.AN2 Therapies is actually reassessing its own company in feedback to lackluster midphase informatio...
.Merck & Co. is actually spending $700 million upfront to challenge Amgen in a blood cancer cells...
.Along With Gilead Sciences on the verge of an FDA choice for its own liver health condition drug se...